GlassScriptPhysician profile
Dmitriy Petrovich Berenzon
NPI 1669631479
$1,731.12
in general payments reported to CMS, 2019-2025
27 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $363 · 2021: $128 · 2022: $395 · 2023: $72.97 · 2024: $144 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $333.86 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $234.48 | 2020-2024 | |
| Genentech USA, INC. | $171.94 | 2019 | |
| Pfizer INC. | $150.21 | 2020-2025 | |
| Amgen INC. | $113.27 | 2019-2022 | |
| Seagen INC. | $61.27 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $58.90 | 2019-2022 | |
| Lilly USA, LLC | $48.54 | 2020-2022 | |
| Emd Serono, INC. | $42.92 | 2020-2022 | |
| Eisai INC. | $42.76 | 2019-2022 | |
| Puma Biotechnology, INC. | $41.98 | 2020-2022 | |
| Abbvie INC. | $39.43 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $38.78 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $36.35 | 2019-2020 | |
| Celgene Corporation | $36.31 | 2020-2025 | Reblozyl |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $36.22 | 2019-2022 | |
| Angiodynamics, INC. | $34.97 | 2019 | |
| Daiichi Sankyo INC. | $29.98 | 2024 | Enhertu |
| Sobi, INC | $27.97 | 2024 | |
| Glaxosmithkline, LLC. | $26.14 | 2025 | Ojjaara |
| Menarini Silicon Biosystems, INC. | $25.02 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.40 | 2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $17.55 | 2022 | |
| Genzyme Corporation | $17.09 | 2020 | |
| Array Biopharma INC | $15.77 | 2024 | Tukysa, Braftovi, Mektovi |
| Mylan Institutional INC. | $14.38 | 2020 | |
| Astellas Pharma US INC | $13.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Berenzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.